Artivion, Inc. (NYSE:AORT - Get Free Report)'s stock price reached a new 52-week high on Thursday . The company traded as high as $32.33 and last traded at $32.25, with a volume of 304340 shares changing hands. The stock had previously closed at $30.06.
Analyst Upgrades and Downgrades
AORT has been the subject of a number of analyst reports. JMP Securities restated a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Needham & Company LLC reiterated a "buy" rating and set a $34.00 price target on shares of Artivion in a research note on Monday, December 9th. Finally, Oppenheimer raised their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $31.80.
View Our Latest Stock Report on AORT
Artivion Stock Down 1.5 %
The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The company has a market capitalization of $1.29 billion, a PE ratio of -1,537.95 and a beta of 1.74. The firm's 50-day simple moving average is $28.77 and its 200 day simple moving average is $27.09.
Insider Activity at Artivion
In other news, VP Andrew M. Green sold 7,618 shares of the firm's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the transaction, the vice president now owns 33,503 shares in the company, valued at $1,005,090. This trade represents a 18.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction on Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the transaction, the chief accounting officer now directly owns 135,660 shares of the company's stock, valued at $4,023,675.60. This trade represents a 3.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,017 shares of company stock worth $600,007 over the last 90 days. Company insiders own 8.10% of the company's stock.
Hedge Funds Weigh In On Artivion
Hedge funds have recently added to or reduced their stakes in the business. FMR LLC grew its position in shares of Artivion by 28.0% in the third quarter. FMR LLC now owns 115,184 shares of the company's stock valued at $3,066,000 after purchasing an additional 25,176 shares during the last quarter. Barclays PLC lifted its stake in Artivion by 346.3% in the 3rd quarter. Barclays PLC now owns 70,877 shares of the company's stock valued at $1,888,000 after buying an additional 54,996 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in Artivion during the 3rd quarter valued at $5,798,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Artivion by 58.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company's stock worth $9,074,000 after buying an additional 125,668 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Artivion by 543.0% in the third quarter. BNP Paribas Financial Markets now owns 28,574 shares of the company's stock worth $761,000 after acquiring an additional 24,130 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.
About Artivion
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Further Reading
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
